Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 44.9% year over year) with net income of $19M.
Q3 2026 key financials · XBRL
- Revenue
- $38M
- +44.9% YoY · −4.8% QoQ
- Net income
- $19M
- +3630.9% YoY · +119.5% QoQ
- Operating margin
- 30.7%
- EPS (diluted)
- $0.29
- +107.1% QoQ
Source: XBRL data from the ZEVRA THERAPEUTICS, INC. (ZVRA) Q3 2026 10-Q on SEC EDGAR. USD.
ZEVRA THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $37.8M, up $11.7M YoY, driven by MIPLYFFA product sales increasing $11.6M
- Net income $19.2M vs $0.5M loss YoY, operating income $11.6M vs $4.1M
- MIPLYFFA strongest product, $11.6M YoY sales increase; OLPRUVA revenue $0.2M and sales efforts scaled back
- Cash, cash equivalents and investments $270.9M; nine-month operating cash flow $33.2M vs $(7.1)M
- EMA CHMP negative opinion on arimoclomol, re-examination requested; continued celiprolol Phase 3 development and commercial spending
Risk Factors
- No material changes to risk factors since the March 31, 2026 Form 10-Q
- Carried-forward risks remain those disclosed in the December 31, 2025 Form 10-K
- Latest risk-factor update filed May 6, 2026 with the SEC
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ZEVRA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.